Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)

  • VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.